TESARO Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Cash & Short Term Investments
130,310.00
256,861.00
230,146.00
785,877.00
643,095.00
Total Accounts Receivable
-
-
679.00
6,195.00
54,716.00
Inventories
-
-
1,106.00
14,700.00
57,939.00
Other Current Assets
4,029.00
1,735.00
4,560.00
10,515.00
32,211.00
Total Current Assets
134,339.00
258,596.00
236,491.00
817,287.00
787,961.00
Net Property, Plant & Equipment
440.00
1,022.00
2,779.00
6,640.00
9,652.00
Total Investments and Advances
-
-
500.00
1,694.00
2,552.00
Intangible Assets
-
-
14,732.00
12,877.00
56,384.00
Other Assets
799.00
4,284.00
779.00
3,795.00
5,636.00
Total Assets
135,578.00
263,902.00
255,281.00
842,293.00
862,185.00
Accounts Payable
1,869.00
-
8,019.00
5,236.00
4,172.00
Other Current Liabilities
10,554.00
24,365.00
38,662.00
71,773.00
162,034.00
Total Current Liabilities
12,423.00
24,365.00
46,681.00
77,009.00
166,206.00
Long-Term Debt
-
115,481.00
121,325.00
131,775.00
437,105.00
Other Liabilities
3.00
-
401.00
5,391.00
9,788.00
Total Liabilities
12,426.00
139,846.00
168,407.00
214,175.00
613,099.00
Common Equity (Total)
123,152.00
124,056.00
86,874.00
628,118.00
249,086.00
Total Shareholders' Equity
123,152.00
124,056.00
86,874.00
628,118.00
249,086.00
Total Equity
123,152.00
124,056.00
86,874.00
628,118.00
249,086.00
Liabilities & Shareholders' Equity
135,578.00
263,902.00
255,281.00
842,293.00
862,185.00

About TESARO

View Profile
Address
1000 Winter Street
Waltham Massachusetts 02451
United States
Employees -
Website http://www.tesarobio.com
Updated 09/14/2018
TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products. It focuses on oncology-based therapeutics and its products include: Rolapitant and Niraparib. The company was founded by Leon Moulder, Jr.